Seeking Alpha News (Fri, 27-Feb 11:38 AM ET)
TipRanks (Fri, 27-Feb 11:11 AM ET)
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Caris Life Sciences, Inc. (CAI)
TipRanks (Fri, 27-Feb 8:50 AM ET)
Guggenheim Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)
TipRanks (Fri, 27-Feb 8:03 AM ET)
Bank of America Securities Keeps Their Buy Rating on Caris Life Sciences, Inc. (CAI)
TipRanks (Fri, 27-Feb 7:59 AM ET)
Caris Life Sciences, Inc. (CAI) Gets a Buy from BTIG
TipRanks (Fri, 27-Feb 7:58 AM ET)
/C O R R E C T I O N -- Caris Life Sciences/
PRNewswire (Thu, 26-Feb 6:59 PM ET)
Caris Life Sciences Completes Interim Readout of Achieve 1 Study
PRNewswire (Thu, 26-Feb 6:00 PM ET)
PRNewswire (Thu, 26-Feb 4:05 PM ET)
PRNewswire (Tue, 24-Feb 8:30 AM ET)
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.
As of March 4, 2026, CAI stock price climbed to $19.79 with 389,261 million shares trading.
CAI has a beta of 1.98, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.15 to the broad based SPY ETF.
CAI has a market cap of $5.58 billion. This is considered a Mid Cap stock.
Last quarter Caris Life Sciences reported $293 million in Revenue and $.28 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.21.
The top ETF exchange traded funds that CAI belongs to (by Net Assets): IBB, IDNA, IWR, IWP, ONEQ.
CAI support price is $18.49 and resistance is $20.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.